Builds on companies’ first-of-its-kind initiative using radiolabeled imaging to understand the impact of the extravascular distribution of factor IX on joint health
Strategic collaboration will seek to advance the adoption of ultrasound imaging in the diagnosis and management of joint disease in people with hemophilia
WALTHAM, Mass. & BOSTON, Mass – August 24, 2017 – Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, and Invicro, LLC, a leading provider of imaging services and analysis for pharmaceutical research and development, today announced that they have formed a strategic collaboration focused on expanding the use and adoption of leading imaging technologies, including ultrasound and radiolabeled imaging, to improve the diagnosis and management of joint disease in people with hemophilia.